The purpose of the study is to determine whether adding dasatinib can change the number and activity of important immune cells, specifically the white‑blood‑cell types called CD4, CD8 and CD56+. Participants will take either dasatinib or placebo for about a year, with regular clinic visits where blood samples are taken at several intervals (early after starting, then roughly every few months) to measure these cells, inflammation signals, and any side effects. Terms such as “viral reservoir” refer to the hidden virus that remains in cells despite treatment, and “inflammation markers” are blood signals that show how much inflammation is present.

Throughout the trial, doctors will closely watch for any adverse events, meaning any unwanted medical problems, and will perform routine laboratory tests to ensure safety. The study will track how the immune cells and inflammation markers change over time, providing information on whether dasatinib can offer additional benefit to people already on antiretroviral therapy.

The purpose of this study is to compare the effectiveness, safety, and tolerability of the two treatment options over a period of time. Participants will be randomly assigned to one of the two groups and will not know which treatment they are receiving, as the study is double-blind. This means that neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The study will last for a total of 96 weeks, with regular check-ups and assessments to monitor the participants’ health and the virus’s response to the treatment.

Throughout the study, the main focus will be on how well the treatments reduce the amount of HIV-1 RNA in the blood, which is a measure of the virus’s activity. Safety will also be closely monitored by reviewing any side effects or adverse events that participants may experience. The study aims to provide valuable information on the best treatment options for people newly diagnosed with HIV-1, helping to improve their health outcomes and quality of life.

The research is divided into two parts. The first part involves a one-day treatment to see how the medications affect the virus within certain cells. The second part involves a four-week treatment to evaluate if the combination of drugs can reduce the overall amount of viral genetic material, known as HIV-DNA, present in the body. Participants may receive the active medications or a placebo.

The goal of the study is to evaluate how well the experimental treatment controls the HIV-1 RNA, which is a measure of the amount of virus in the blood. The research also aims to monitor the safety and how well the body tolerates the medications over time. During the course of the study, participants will be observed for a set period to track changes in their viral levels and their CD4+ T-cell count, which is a type of white blood cell that helps the body fight infections.

The study is divided into two stages. In the first stage, the effectiveness and safety of the weekly treatment are assessed in an open manner. In the second stage, a more controlled method is used where neither the participants nor the researchers know which specific treatment is being administered to ensure unbiased results. Participants will be monitored through various stages of the study to collect data on how the virus responds to the treatment and to identify any potential side effects.

The purpose of this study is to find out how well the investigational treatment containing VH4524184 works in reducing the amount of virus in the blood compared to the approved treatment, and to check how safe these treatments are. The study will look at whether the amount of virus in the blood drops to very low levels and stays low during the treatment period. The study will also measure changes in certain blood cells that are important for the immune system and will check for any side effects that may occur during treatment.

People who join this study will be assigned to receive one of the treatment combinations and will take their assigned medicine for up to 24 months. During this time, they will have regular visits where blood samples will be collected to measure the amount of virus in the blood and to check their overall health. The study will monitor how well the treatment works and how people respond to it over time. The study is expected to start in early 2026 and continue until late 2028.

During the study, participants will start taking both venetoclax and ART at the same time. The study will last for about one year, during which time researchers will carefully monitor participants for any side effects or health changes. Blood samples will be collected throughout the study to measure different things, including how much HIV virus is present in the blood and how many immune cells contain the virus. The researchers will look at special types of cells called CD4+ T cells, which are important immune cells that HIV attacks. They will use several laboratory tests to count how many of these cells contain HIV genetic material, which is called HIV-DNA and HIV RNA. Some of these tests have specific names like the Intact Proviral DNA Assay or IPDA, which helps identify cells that contain complete copies of the virus that could potentially produce new virus particles.

The researchers will also track how quickly the amount of virus in the blood decreases after treatment starts, and they will examine different types of immune cells including B cells and CD8+ T cells to see how they change during treatment. Throughout the study, all health problems and side effects will be recorded and assessed to determine whether they are related to the study medication. This information will help researchers understand whether venetoclax can be safely used together with standard HIV treatment and whether it might help reduce the amount of virus that stays hidden in the body even when people are taking their regular HIV medications.

The study uses film-coated tablets that contain either the active medications or placebo. Participants will receive either MK-8527 once per month or the combination of emtricitabine and tenofovir once per day. The study will monitor how well these medications prevent HIV-1 infection and evaluate their safety over time.

During the study, participants will take their assigned medication as directed and attend regular medical visits. The medications are taken by mouth, and the study team will track any health changes that occur. The study will look at how many people develop HIV-1 infection while taking the medications and monitor any side effects that may occur.

The study involves taking small samples from lymph nodes and blood to analyze how the immune system responds to vaccination. Participants will receive a single dose of one of the pneumococcal vaccines through an intramuscular injection. The researchers will monitor the immune response for up to 6 months after vaccination by collecting blood samples and small amounts of saliva.

The research aims to understand how factors like age and HIV infection influence the body’s response to different types of vaccines. This knowledge could help improve vaccination strategies for different groups of people. The study will also look at how lifestyle factors such as diet, exercise, and smoking might affect the immune response to vaccination.

The purpose of the study is to compare the effectiveness and safety of Lenacapavir with the combination of Emtricitabine and Tenofovir Disoproxil Fumarate in people who could benefit from HIV prevention. Participants will receive either the Lenacapavir injection twice a year or the oral combination medication. The study will monitor how well these treatments work in preventing HIV over a period of time, as well as their safety and how acceptable they are to participants.

Throughout the study, participants will have regular visits to receive their treatment and undergo health assessments. The study aims to provide valuable information on the long-term use of Lenacapavir for HIV prevention, helping to determine if it is a safe and effective option for people at risk of acquiring HIV.

The purpose of the study is to evaluate the safety and effectiveness of this medication when taken once daily as a preventive measure, also known as pre-exposure prophylaxis. Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will follow participants for a minimum of 48 weeks, with at least half of the participants being followed for 96 weeks. During this time, the study will monitor the occurrence of HIV-1 infections among participants.

Throughout the study, various health assessments will be conducted, including checks on bone health and kidney function. These assessments will help determine any changes in the body that may occur as a result of taking the medication. The study aims to provide valuable information on how well the medication works in preventing HIV-1 infection and its safety for long-term use.

Participants in the study will receive the Shingrix vaccine through an injection into the muscle. The study will monitor the immune response by measuring specific antibodies and immune cells at different times after vaccination. The study will also track any side effects that occur after receiving the vaccine. The trial will last for several months, with follow-up visits to assess the immune response and overall health of the participants.

The study aims to provide valuable information on the effectiveness of the recombinant Zoster Vaccine in people living with HIV compared to those without the virus. This information could help improve vaccination strategies and health outcomes for individuals over 50 years old, particularly those with HIV. Participants will contribute to important research that may benefit others in the future.

The purpose of the study is to assess how safe baricitinib is for people with HIV-1 who are already on a stable treatment plan that keeps the virus under control. The study will also look at how baricitinib affects certain cells in the immune system, specifically CD4+ T cells, which are important for fighting infections. Participants will take the medication for 12 weeks, and their health will be monitored through regular blood tests and check-ups to ensure their safety and to observe any changes in their immune system.

Throughout the study, researchers will measure various markers in the blood to understand how baricitinib affects the body. These markers include levels of certain proteins and the amount of HIV-1 DNA in the cells. The study will help determine if baricitinib can be a safe and effective addition to the current treatment options for people living with HIV-1. Participants will be closely monitored for any side effects or changes in their health during the study period.

Participants in the study will be randomly assigned to receive either colchicine or a placebo. The trial will last for 96 weeks, during which time the effects of the treatment on coronary artery inflammation will be monitored. The study will also look at changes in heart plaque, which is a buildup of substances in the arteries, and other markers of inflammation in the blood. These assessments will help determine if colchicine can effectively reduce heart-related risks in the study participants.

The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving colchicine or the placebo until the study is completed. This approach helps ensure that the results are unbiased. The ultimate goal is to understand whether colchicine can be a beneficial treatment for reducing heart disease risk in people with HIV, potentially leading to better health outcomes for this population.

The purpose of the study is to evaluate how well the new weekly treatment works compared to Biktarvy in people who have not received any prior treatment for their HIV-1 infection. Participants in the study will be randomly assigned to receive either the new weekly treatment or Biktarvy. The study will last for up to 48 weeks, during which participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study aims to see if the new treatment can maintain low levels of the virus in the blood, similar to Biktarvy.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study will also collect information on how the new treatment affects the immune system and the levels of the virus in the blood over time. This research is important for developing new treatment options for people living with HIV-1, potentially offering a more convenient weekly dosing schedule compared to daily medication.

Participants in the study will switch from their current oral antiretroviral therapy (ART) to the new treatment with Cabotegravir and Rilpivirine injections. The study will last for 96 weeks, which is a little less than two years. During this time, participants will receive regular injections and have their health monitored to see how well the treatment is working and to check for any side effects.

The study aims to see if the new treatment can keep the virus at low levels in the blood, specifically looking at the number of virus copies per milliliter of blood. This is important for managing HIV-1 and ensuring that the virus does not become active again. The results will help determine if this new treatment approach is effective for older adults living with HIV-1.

Participants in the study will receive the Gardasil 9 vaccine, which is given as an injection. The study will monitor the participants over a period of time to see how their bodies respond to the vaccine. This includes checking for the production of antibodies, which are proteins made by the immune system to help fight infections. The study will also look at the safety of the vaccine in this group of women.

The study will take place over several months, with key assessments happening at the start and then again at seven months. The goal is to see if the vaccine can produce a strong immune response, similar to what is seen in people without HIV. This information will help determine if the vaccine is effective and safe for women living with HIV.

The purpose of the study is to determine if these two-drug combinations can keep the virus under control as effectively as the current three-drug treatments. Participants in the study will take one of the two-drug combinations and will be monitored over a period of time to see if the virus remains suppressed. The study will last for about 48 weeks, with regular check-ups to monitor the participants’ health and the effectiveness of the treatment.

Throughout the study, participants will have their blood tested to measure the amount of virus present and to check for any side effects. The study will also look at other health indicators, such as immune cell counts and metabolic markers, to ensure the treatments are safe and effective. The goal is to find a simpler treatment option that is just as effective as the current standard, making it easier for people living with HIV to manage their condition.

The purpose of the study is to see if these injections can better control the virus in people who have not responded well to their current oral HIV treatments. Participants will receive injections of REKAMBYS and Vocabria every two months for a period of six months. The study will compare the effectiveness of these injections to the standard oral treatments that participants are currently taking.

Throughout the study, participants will be monitored to see how well the virus is controlled and to check for any side effects. The goal is to find out if the injectable treatment can provide better viral suppression, which means reducing the amount of virus in the blood, compared to the oral treatments. This study will help determine if the injectable treatment is a better option for people with HIV-1 who have not had success with their current medications.

The purpose of the study is to evaluate the effectiveness and safety of the new weekly treatment compared to the existing daily treatment. Participants will be randomly assigned to one of the two groups. The study will be conducted in two phases. In the first phase, the effectiveness of the weekly treatment will be assessed over 24 weeks. In the second phase, the study will continue for up to 48 weeks to further evaluate the long-term effects of the treatments.

Throughout the study, participants will have regular check-ups to monitor their health and the levels of the virus in their blood. The study aims to provide valuable information on whether the new weekly treatment can be a safe and effective alternative to the current daily regimen for people living with HIV-1.

The purpose of the study is to evaluate the effectiveness and safety of this early switch to the two-drug regimen compared to continuing the current three-drug treatment. Participants will be monitored over a period of 96 weeks. Initially, the study will focus on the first 48 weeks to see if the new regimen maintains viral suppression. After this period, those in the control group will also switch to the two-drug regimen, and the final evaluation will occur at the end of the study.

Throughout the study, various health parameters will be assessed, including changes in immune cell counts, the presence of any drug resistance, and overall safety. The study will also look at changes in metabolic health, mental health, and quality of life. Participants will undergo regular check-ups to ensure their well-being and to gather data on the effectiveness of the treatment switch.

Participants in the study will receive either the antibody treatment or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study aims to observe how well the antibodies work in keeping the virus under control over a period of 20 weeks after stopping standard treatment. The trial will also monitor the safety of the treatment by checking for any side effects or adverse reactions.

Throughout the study, participants will have regular check-ups to measure their immune system’s response, including the levels of CD4 T cells, which are a type of white blood cell important for fighting infections. The study will also track how long the virus remains undetectable in the blood and how quickly it returns if it does. The goal is to understand if these antibodies can provide a new way to manage HIV without continuous medication.

Participants in the study will take the medications orally, in the form of tablets, over a period of time. The goal is to see if the new combination of DTG/3TC is as effective as the current standard treatment in keeping the virus under control, which is referred to as “virological suppression.” The study will monitor the children’s health and the virus levels in their blood at various points, such as weeks 24, 48, and 96, to ensure the treatment is working effectively.

Throughout the study, researchers will also observe any side effects or changes in the children’s health, including their immune system’s response, any new symptoms, and overall well-being. The trial is designed to ensure that the new treatment is safe and effective for children with HIV, providing valuable information for future treatment options.

Participants in the study will be randomly assigned to either continue their current standard treatment or switch to the new weekly oral regimen. The study will monitor the participants’ health and the level of the virus in their blood at various points, including at 48 weeks and 96 weeks. The study will also look at changes in the participants’ immune cell counts, specifically CD4 T-cells, which are important for fighting infections.

The study will involve taking medication by mouth, and participants will be closely monitored for any side effects or changes in their health. The trial aims to provide more information on whether the new treatment can be a viable option for people living with HIV-1 who are already managing their condition well with existing treatments.

The purpose of the study is to evaluate the effectiveness of switching to the weekly Islatravir/Lenacapavir regimen compared to continuing the daily Biktarvy regimen. Participants will be randomly assigned to one of the two groups and will not know which treatment they are receiving. The study will last for 48 weeks, during which participants will have regular check-ups to monitor their health and the level of the virus in their blood. The main goal is to see if the new weekly treatment is as effective as the daily treatment in keeping the virus suppressed.

Throughout the study, participants will be closely monitored for any changes in their health, including their immune cell counts, which are important for fighting infections. The study will also track any side effects that may occur from the treatments. This research aims to provide more options for people living with HIV-1, potentially offering a more convenient weekly treatment regimen.

The purpose of the study is to evaluate how well the combination of Doravirine and Raltegravir can maintain the suppression of the virus in patients who are already successfully managing their HIV with other treatments. Participants will be monitored over a period of time to see if the virus remains suppressed. The study will also look at the health of the immune system by measuring certain types of cells in the blood, and it will assess the quality of life of the participants through questionnaires.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study will also track any changes in the virus and any potential side effects of the medications. This research aims to provide more information on the effectiveness of this dual therapy in maintaining viral suppression in people living with HIV.

The purpose of the study is to evaluate how effective it is to switch from a standard three-drug antiretroviral therapy to a two-drug therapy using doravirine and dolutegravir sodium in people who already have an undetectable viral load, meaning the virus is not currently detectable in their blood. Participants in the study will take these medications orally for a period of up to 96 weeks. During this time, the study will monitor the participants’ viral load at various intervals to ensure it remains undetectable, as well as assess the safety and tolerability of the treatment.

Throughout the study, participants will have their health closely monitored, including regular checks of their immune system’s health through CD4 counts, which measure a type of white blood cell that is important for fighting infections. The study will also track any side effects or adverse events that may occur, and participants will be asked to complete questionnaires about their quality of life and satisfaction with the treatment. The goal is to determine if this two-drug therapy is a safe and effective option for maintaining control of HIV in people who are already successfully managing the virus with their current treatment.

Participants in this study will continue to take rilpivirine along with other medications that help manage HIV-1. The study is designed to ensure that those who have been benefiting from rilpivirine can keep receiving it. The treatment period in this study can last up to 120 days. During this time, participants will be monitored to ensure they continue to experience positive effects from the medication.

This study is open-label, meaning that both the participants and the researchers know which treatment is being administered. There is no primary endpoint defined for this study, which means it is primarily focused on providing ongoing treatment rather than measuring specific outcomes. Participants will continue to receive rilpivirine as long as they are benefiting from it, according to the judgment of the study investigators.

The purpose of the study is to evaluate the safety and effects of IMC-M113V in people who have chronic HIV infection and are already on antiretroviral therapy (ART), a common treatment for HIV. The study is divided into two parts. In the first part, participants will receive a single dose of the treatment to see how their bodies react. In the second part, participants will receive multiple doses over a period of time, up to at least 12 weeks, to further assess the treatment’s safety and how well it is tolerated.

Throughout the study, researchers will monitor participants for any side effects and changes in their health. They will also check how the body processes the treatment and whether it affects the levels of HIV in the blood. The study aims to find a safe and effective dosing schedule for IMC-M113V that could be used in future research. Participants will continue their regular HIV treatment during the study, and their health will be closely watched by the research team.

The purpose of the study is to evaluate the effectiveness of these treatments in people who have not received any prior treatment for their HIV-1 infection. Participants will be randomly assigned to receive one of the treatment regimens. The study will last for a period of 24 months, during which participants will take the medication orally, in the form of film-coated tablets, once a day. Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment.

The main goal is to see how well the treatments work in reducing the amount of the virus in the blood to very low levels. The study will also look at other health factors, such as weight changes, blood pressure, and any side effects that may occur. This information will help determine the best treatment options for people living with HIV-1 infection.

The purpose of the study is to investigate the safety and effectiveness of fostemsavir in people whose current HIV treatments are no longer working effectively. Participants in the study will receive either fostemsavir or a placebo, in addition to their existing treatment regimen. The study will monitor changes in the amount of HIV in the blood and other health indicators over a period of time, including up to 96 weeks.

Throughout the study, participants will have regular check-ups to assess their health and the impact of the treatment. The study aims to provide valuable information on how fostemsavir can help manage HIV-1 in patients who have limited treatment options due to drug resistance. This research is important for developing new strategies to improve the lives of people living with HIV-1.

The purpose of this study is to compare the effectiveness of these two treatments in maintaining control over the virus in people living with HIV. Participants in the study will be randomly assigned to receive either Dovato or Biktarvy. The study will last for a period of up to 96 weeks, during which participants will take their assigned medication daily. Throughout the study, participants will have regular check-ups to monitor their health and the level of the virus in their blood.

This trial aims to determine if Dovato is as effective as Biktarvy in keeping the virus under control. Participants will be closely monitored to ensure their safety and to gather information on how well each treatment works. The study is designed to provide valuable insights into the management of HIV, potentially leading to improved treatment options for those living with the virus.

Participants in the study will receive these medications in the form of film-coated tablets, which are taken orally. The study will be conducted over a period of up to 24 months. During this time, researchers will monitor the participants to see how the size of the latent reservoir of the virus changes. This will involve measuring the total and intact proviral DNA, which is a way to assess the amount of virus that remains hidden in the body.

The trial is open-label, meaning both the researchers and participants will know which medications are being administered. It is a randomized and controlled study, which helps ensure that the results are reliable. The study aims to provide valuable insights into how high doses of these antiretroviral drugs can potentially eliminate the hidden virus in people living with HIV.

Participants in the study will continue their current ART regimen during the first phase of the trial. In the second phase, they will stop taking ART to see how well Pomalidomide helps control the virus on its own. Some participants will receive Pomalidomide, while others will receive placebo capsules. The study will monitor the safety of Pomalidomide and how it affects the virus levels in the body.

The trial will also look at how the immune system responds to the virus during the study. This includes measuring the levels of certain cells in the blood that are important for fighting infections. The study aims to provide more information on whether Pomalidomide can be an effective treatment option for people living with HIV.

Participants in the study will receive the medications in different forms: Sunlenca as a 300 mg film-coated tablet and a 464 mg solution for injection, and Vocabria as a 30 mg film-coated tablet and a 600 mg prolonged-release suspension for injection. The study will monitor the participants’ health and the virus levels in their blood to see how well the treatment works. The study will also look at any side effects that may occur and how the participants feel about the treatment.

The study will last for about 48 weeks, during which participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. The goal is to maintain control over the virus without it becoming resistant to the medications. Participants will be observed for any signs of the virus becoming active again, which is known as virological failure. The study will also assess the participants’ satisfaction with the treatment and any changes in their overall health, including weight and metabolic parameters like cholesterol and blood sugar levels.

Participants in the study will take the medications orally, meaning they will swallow the tablets. The study will last for a period of time, during which the participants will be monitored to see how their bodies respond to the treatment. The study will also look at how well the medications are tolerated by the participants, which means checking for any side effects or reactions to the treatment. The study aims to ensure that the combination of Bictegravir and Lenacapavir is both safe and effective for children and adolescents with HIV-1.

Throughout the study, the participants’ health will be closely observed, and their response to the treatment will be assessed. This includes measuring the levels of the virus in their blood and checking for any changes in their immune system. The study will also gather feedback from participants about how they feel about taking the medication, including its taste and ease of use. The goal is to confirm the appropriate dosage and ensure the treatment is suitable for young people with HIV-1.

The main purpose of the study is to determine how well people maintain their PrEP treatment over time when using either injectable cabotegravir or oral Truvada tablets. The study will last for 24 months, during which participants will receive either cabotegravir (starting with 30 mg tablets followed by 600 mg injections) or Truvada tablets (containing 200 mg emtricitabine and 245 mg tenofovir disoproxil).

Throughout the study, participants will attend regular medical visits where their health will be monitored. These visits will include various health assessments, blood tests, and questionnaires about their experiences with the medication. The study will track how consistently participants use their assigned medication and evaluate its effectiveness in preventing HIV infection.

Participants in the study will take the new medication orally, which means it is taken by mouth. The study will last for 48 weeks, during which time the researchers will monitor the participants’ health and the level of the virus in their blood. The main goal is to see how many participants have a viral load, which is the amount of virus in the blood, of 50 copies/mL or more at the end of the study period. The study will also look at other health indicators, such as the number of certain immune cells and any side effects experienced by the participants.

Throughout the study, participants will be asked to report any changes in their quality of life and overall health. This information will help researchers understand the benefits and potential challenges of switching to fostemsavir trometamol. The study will also assess the possibility of interactions between the new medication and other drugs the participants may be taking. This trial aims to provide valuable insights into the treatment of HIV-1 for those who have limited options available to them.

The purpose of the study is to assess how safe it is for participants to switch from their current injectable treatment to the oral medication Biktarvy. Participants in the study will take Biktarvy tablets daily for a period of 24 weeks. During this time, researchers will monitor the participants’ health and the levels of the virus in their blood. The study will also look at how satisfied participants are with their new treatment compared to their previous one.

Throughout the study, participants will have regular check-ups to ensure their safety and to track any changes in their health. The study will also measure the concentration of the medications in the blood at different points in time. This information will help researchers understand how well the new treatment works and if there are any side effects. The trial is designed to provide valuable insights into the potential benefits of switching to an oral treatment for managing HIV-1 infection.

The purpose of the study is to assess the safety of reducing treatment while maintaining control over the Hepatitis B virus in patients who have previously been on continuous triple therapy for their co-infection. The study will last for 96 weeks, during which participants will be monitored to ensure that the viral infections remain under control. Participants will receive either a combination of darunavir boosted with ritonavir and lamivudine, or a combination of dolutegravir sodium and lamivudine. The study will also include a group receiving a placebo for comparison.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment strategies. The main focus will be on ensuring that the Hepatitis B virus remains controlled, while also observing the impact on the HIV-1 virus. The study will also look at the participants’ quality of life and any side effects they may experience. This research is important for understanding how to safely reduce medication in patients with these co-infections while maintaining their health.

The purpose of the study is to evaluate the anti-aging effect of Metformin compared to a placebo. Participants will be randomly assigned to one of the two groups and will not know which treatment they are receiving. The study will last for a period of 96 weeks, during which participants will undergo regular assessments to monitor changes in their biological age. Biological age refers to how old a person seems based on various health markers, rather than their actual age in years.

Throughout the study, researchers will use different methods to measure changes in biological age, including looking at specific markers in the blood that are associated with aging. The trial will also monitor other health indicators, such as immune system function and inflammation levels, to understand the broader effects of Metformin on aging in people with HIV. The findings from this study could provide valuable insights into new ways to support healthy aging in individuals living with HIV.